Bio Sequence

How To Obtain Target-Related Sequences Directly Through Target Name And Perform Sequence Alignment?

23 November 2023
2 min read

Taking HER2 target as an example, suppose you are very concerned about antibody drugs related to the HER2 target, and you want to inquire about the publicly available antibody sequences for the HER2 target worldwide. This article will teach you how to search for related sequences with one click through the target name.

First of all, register for a free Patsnap Bio Sequence Database account. On the homepage of the database, select "Gene" in the drug/gene index portal, enter the target name HER2 directly, and then click search.

You can then filter the 1,563 sequence results searched out through the filters on the left side. Check "Yes" in the "Antibody" item of the filter, and check the name of the drug you want to search for in the "Drug" item of the filter, such as Pertuzumab, Trastuzumab, SHR-A1811, etc. After the screening and filtering, you will see 5 sequence results.

Further select all sequences and save them to your workspace. Go to the workspace, select the saved 5 sequences, and then click "Align Sequences" to carry out a very clear online comparison of CDR fragment highlights.

It is important to note that Patsnap Bio is the most extensive sequence search platform for the Patsnap database. It incorporates AI with human-curated data for comprehensive handling of protein and nucleotide sequence data plucked from global patents, biological periodicals, and public repositories. Essential biological sequences are manually annotated, illuminating structural modifications to provide the most accurate sequence data and boost sequence retrieval efficiency.

Free registration is available for the Bio biological sequence database: https://bio.patsnap.com. Act now to expedite your sequence search tasks.

Kyverna Therapeutics announces Phase 2 trial approval for KYV-101, a full human CD19 CAR T-Cell therapy for Myasthenia Gravis, by the FDA
Latest Hotspot
3 min read
Kyverna Therapeutics announces Phase 2 trial approval for KYV-101, a full human CD19 CAR T-Cell therapy for Myasthenia Gravis, by the FDA
22 November 2023
Kyverna Therapeutics reveals FDA approval for Phase 2 study of KYV-101, a complete human CD19 CAR T-Cell treatment for Myasthenia Gravis.
Read →
MDNA-11: A Quick Look at Its R&D Progress and Clinical Results from the 2023 SITC
MDNA-11: A Quick Look at Its R&D Progress and Clinical Results from the 2023 SITC
22 November 2023
On Oct 31, 2023, the latest clinical data of MDNA11 monotherapy in a phase 1/2 study on advanced solid tumors was reported at SITC Congress, showing potential efficacy for future research.
Read →
Latest updates on PACIFIC-2 Phase III trial studying Imfinzi with chemo and radiation for inoperable Stage III non-small cell lung cancer
Latest Hotspot
3 min read
Latest updates on PACIFIC-2 Phase III trial studying Imfinzi with chemo and radiation for inoperable Stage III non-small cell lung cancer
22 November 2023
Latest news on PACIFIC-2 Phase III study of Imfinzi given along with platinum-based chemo and radiotherapy for Stage III non-small cell lung cancer that can't be surgically removed.
Read →
Mozart Therapeutics presents MTX-101 trial outcomes, a dual-action CD8 Treg modifier for autoimmune treatment, at 2023 ACR Convergence
Latest Hotspot
3 min read
Mozart Therapeutics presents MTX-101 trial outcomes, a dual-action CD8 Treg modifier for autoimmune treatment, at 2023 ACR Convergence
22 November 2023
Mozart Therapeutics shares trial results for MTX-101, a unique dual-action CD8 Treg adjuster used for treating autoimmune diseases, at the 2023 American College of Rheumatology Convergence.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.